Effectiveness and safety of rivaroxaban for anticoagulation therapy in COVID-19

From the Department of Pulmonary and Critical Care Medicine (Shen), Jiangxi PingXiang People’s Hospital, Pingxiang, Jiangxi Province, from the Department of Trauma Center (Qiu, Zhu, Zeng); and from the Department of Critical Care Medicine (Liu), Zhuzhou Central Hospital, Zhuzhou, Hunan Province, China.

From the Department of Pulmonary and Critical Care Medicine (Shen), Jiangxi PingXiang People’s Hospital, Pingxiang, Jiangxi Province, from the Department of Trauma Center (Qiu, Zhu, Zeng); and from the Department of Critical Care Medicine (Liu), Zhuzhou Central Hospital, Zhuzhou, Hunan Province, China.

From the Department of Pulmonary and Critical Care Medicine (Shen), Jiangxi PingXiang People’s Hospital, Pingxiang, Jiangxi Province, from the Department of Trauma Center (Qiu, Zhu, Zeng); and from the Department of Critical Care Medicine (Liu), Zhuzhou Central Hospital, Zhuzhou, Hunan Province, China.

From the Department of Pulmonary and Critical Care Medicine (Shen), Jiangxi PingXiang People’s Hospital, Pingxiang, Jiangxi Province, from the Department of Trauma Center (Qiu, Zhu, Zeng); and from the Department of Critical Care Medicine (Liu), Zhuzhou Central Hospital, Zhuzhou, Hunan Province, China.

From the Department of Pulmonary and Critical Care Medicine (Shen), Jiangxi PingXiang People’s Hospital, Pingxiang, Jiangxi Province, from the Department of Trauma Center (Qiu, Zhu, Zeng); and from the Department of Critical Care Medicine (Liu), Zhuzhou Central Hospital, Zhuzhou, Hunan Province, China.